| Dr Cynthia Chinn, MD | |
|
525 N Garfield Ave, Monterey Park, CA 91754-1202 | |
| (626) 573-2222 | |
| Not Available |
| Full Name | Dr Cynthia Chinn |
|---|---|
| Gender | Female |
| Speciality | Anesthesiology |
| Experience | 13 Years |
| Location | 525 N Garfield Ave, Monterey Park, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427355981 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | A115596 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Garfield Medical Center | Monterey park, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Medvantage Anesthesia Care Inc | 8628350584 | 15 |
News Archive
The Prostate Cancer Foundation today announced that it has funded 14 new Creativity Awards for advanced prostate cancer research. These two-year awards are designed to support innovative research ideas that have the potential to achieve breakthroughs for improved prostate cancer diagnosis and treatment.
CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious disease, has filed a request with the U.S. Food and Drug Administration for designation of its lead product candidate, Neutrolin Catheter Lock Solution, as a qualified infectious disease product (QIDP) pursuant to the Generating Antibiotic Incentives Now (GAIN) title of the Food and Drug Administration Safety and Innovation Act.
Researchers at Virginia Commonwealth University Massey Cancer Center are reporting promising results from laboratory and animal experiments involving a new combination therapy for multiple myeloma, the second most common form of blood cancer.
Research into the controversial drug thalidomide reveals that the mechanism through which the drug causes limb defects is the same process which causes it to damage internal organs and other tissues. The article, published in Bio-Essays, outlines the challenges surrounding thalidomide research and claims that confirmation of a 'common mechanism' could lead to new treatments for Leprosy, Crohn's Disease, AIDS and some forms of cancer..
› Verified 6 days ago
| Entity Name | Medvantage Anesthesia Care Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598110066 PECOS PAC ID: 8628350584 Enrollment ID: O20170130000748 |
News Archive
The Prostate Cancer Foundation today announced that it has funded 14 new Creativity Awards for advanced prostate cancer research. These two-year awards are designed to support innovative research ideas that have the potential to achieve breakthroughs for improved prostate cancer diagnosis and treatment.
CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious disease, has filed a request with the U.S. Food and Drug Administration for designation of its lead product candidate, Neutrolin Catheter Lock Solution, as a qualified infectious disease product (QIDP) pursuant to the Generating Antibiotic Incentives Now (GAIN) title of the Food and Drug Administration Safety and Innovation Act.
Researchers at Virginia Commonwealth University Massey Cancer Center are reporting promising results from laboratory and animal experiments involving a new combination therapy for multiple myeloma, the second most common form of blood cancer.
Research into the controversial drug thalidomide reveals that the mechanism through which the drug causes limb defects is the same process which causes it to damage internal organs and other tissues. The article, published in Bio-Essays, outlines the challenges surrounding thalidomide research and claims that confirmation of a 'common mechanism' could lead to new treatments for Leprosy, Crohn's Disease, AIDS and some forms of cancer..
› Verified 6 days ago
| Entity Name | Hypnos Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295449866 PECOS PAC ID: 9234583402 Enrollment ID: O20230922000468 |
News Archive
The Prostate Cancer Foundation today announced that it has funded 14 new Creativity Awards for advanced prostate cancer research. These two-year awards are designed to support innovative research ideas that have the potential to achieve breakthroughs for improved prostate cancer diagnosis and treatment.
CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious disease, has filed a request with the U.S. Food and Drug Administration for designation of its lead product candidate, Neutrolin Catheter Lock Solution, as a qualified infectious disease product (QIDP) pursuant to the Generating Antibiotic Incentives Now (GAIN) title of the Food and Drug Administration Safety and Innovation Act.
Researchers at Virginia Commonwealth University Massey Cancer Center are reporting promising results from laboratory and animal experiments involving a new combination therapy for multiple myeloma, the second most common form of blood cancer.
Research into the controversial drug thalidomide reveals that the mechanism through which the drug causes limb defects is the same process which causes it to damage internal organs and other tissues. The article, published in Bio-Essays, outlines the challenges surrounding thalidomide research and claims that confirmation of a 'common mechanism' could lead to new treatments for Leprosy, Crohn's Disease, AIDS and some forms of cancer..
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Cynthia Chinn, MD Po Box 25033, Santa Ana, CA 92799-5033 Ph: (714) 347-1010 | Dr Cynthia Chinn, MD 525 N Garfield Ave, Monterey Park, CA 91754-1202 Ph: (626) 573-2222 |
News Archive
The Prostate Cancer Foundation today announced that it has funded 14 new Creativity Awards for advanced prostate cancer research. These two-year awards are designed to support innovative research ideas that have the potential to achieve breakthroughs for improved prostate cancer diagnosis and treatment.
CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious disease, has filed a request with the U.S. Food and Drug Administration for designation of its lead product candidate, Neutrolin Catheter Lock Solution, as a qualified infectious disease product (QIDP) pursuant to the Generating Antibiotic Incentives Now (GAIN) title of the Food and Drug Administration Safety and Innovation Act.
Researchers at Virginia Commonwealth University Massey Cancer Center are reporting promising results from laboratory and animal experiments involving a new combination therapy for multiple myeloma, the second most common form of blood cancer.
Research into the controversial drug thalidomide reveals that the mechanism through which the drug causes limb defects is the same process which causes it to damage internal organs and other tissues. The article, published in Bio-Essays, outlines the challenges surrounding thalidomide research and claims that confirmation of a 'common mechanism' could lead to new treatments for Leprosy, Crohn's Disease, AIDS and some forms of cancer..
› Verified 6 days ago
Daniel Garcia, Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 525 N Garfield Ave, Monterey Park, CA 91754 Phone: 626-307-2120 | |
Dr. Igor Lovrincevic, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 525 N Garfield Ave, Monterey Park, CA 91754 Phone: 716-861-7784 | |
Dae Yong Lee, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 880 S Atlantic Blvd, Ste G 10, Monterey Park, CA 91754 Phone: 626-872-6261 Fax: 626-872-1948 | |
Dr. Claudia Villalpando Leon, D.O Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 525 N Garfield Ave, Monterey Park, CA 91754 Phone: 626-573-2222 Fax: 626-307-2186 | |
Dr. Cynthia Rita Dabish, M.D. Anesthesiology Medicare: Medicare Enrolled Practice Location: 525 N Garfield Ave, Monterey Park, CA 91754 Phone: 626-573-2222 | |
Dr. Pei-jen Hwang, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 235 W Gleason St, Monterey Park, CA 91754 Phone: 813-598-8693 |